Glucotrack, Inc. (GCTK) · Oct 29, 2026 · Delisting
Nasdaq delisting — $0.87 closing bid price vs. $1.00 requirement
Glucotrack’s delisting is now set after a $0.87 close broke its Nasdaq exception, forcing a move toward OTC trading as clinical work continues.
Glucotrack is a pre-commercial medical-device company developing a fully implantable continuous blood-glucose monitor, with its current business story centered on advancing U.S. clinical testing and an FDA Investigational Device Exemption rather than product revenue.
The Nasdaq rescue has failed. The company had been given until November 9, 2026, to maintain a closing bid price of at least $1.00, but Nasdaq determined that its $0.87 close on October 14 did not satisfy the exception.
This is worse than the standing expectation. The market already knew Glucotrack faced delisting risk, but the operative assumption after the Panel exception was that it still had until November 9 to regain compliance. The filing removes that path early and says Nasdaq trading will be suspended at the October 30 open. 〔0〕
The business is not being shut down, but its financing and visibility become harder. Glucotrack says it expects its shares to move to OTC Markets and intends to apply for OTCID trading. 〔1〕 That preserves a potential trading venue, but it is a weaker market structure while the company is still funding and executing a clinical-development program.
The delisting complicates the CBGM story rather than changing the technology milestone path. The filing does not report a new clinical setback, FDA rejection, or cancellation of the U.S. program; the damage is primarily to market access, investor visibility, and potentially future capital-raising flexibility. The company’s core product remains pre-commercial, so this is a meaningful corporate setback even though it does not directly invalidate the device program.
Bottom line: Glucotrack loses its Nasdaq listing after failing the $1.00 bid-price test, replacing a possible compliance recovery with an OTC transition. The clinical program survives, but the company’s capital-markets position is clearly weaker at a critical development stage.
Nasdaq suspension at the open October 30
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!